Core Insights - Equillium, Inc. has successfully closed financing of up to $50 million, with an initial tranche of $30 million expected to fund operations through 2027 [4][11] - The company is advancing the development of EQ504, a novel oral Aryl Hydrocarbon Receptor (AhR) modulator aimed at treating ulcerative colitis, with a Phase 1 clinical study planned for mid-2026 [3][6] Financial Highlights - For the third quarter of 2025, Equillium reported no revenue, a decrease from $12.2 million in the same period of 2024 [7] - Research and development expenses for the third quarter of 2025 were $1.3 million, down from $9.6 million in the same quarter of 2024, primarily due to reduced clinical development costs [8] - General and administrative expenses remained stable at $3.3 million for the third quarter of 2025, unchanged from the same period in 2024 [10] - The net loss for the third quarter of 2025 was $4.2 million, or $(0.06) per share, compared to a net loss of $7,000, or $(0.00) per share in the same quarter of 2024 [10] Corporate Developments - The company hosted a key opinion leader (KOL) event on November 5, 2025, discussing the role of AhR modulation in treating immune-mediated diseases and the potential of EQ504 in ulcerative colitis [5] - The financing was led by new investors including ADAR1 Capital Management and Janus Henderson Investors, with participation from other investors [4] Upcoming Milestones - The initiation of the Phase 1 clinical study for EQ504 is anticipated in mid-2026, with plans to include ulcerative colitis patient cohorts following initial study phases [6]

Core Insights - Equillium, Inc. is hosting a virtual key opinion leader event on November 5, 2025, focusing on the unmet needs and treatment landscape in ulcerative colitis, particularly the potential of Aryl Hydrocarbon Receptor (AhR) modulation [1][2] Company Overview - Equillium is a clinical-stage biotechnology company specializing in developing novel therapeutics for severe autoimmune and inflammatory disorders with high unmet medical needs [5] - The company's pipeline includes several novel immunomodulatory assets targeting immuno-inflammatory pathways [5] Event Details - The event will feature experts Francisco J. Quintana, PhD, and Brian Feagan, MD, discussing the evolving treatment landscape in ulcerative colitis and the promise of AhR targeting [2] - Company management will present a scientific overview of EQ504, an oral, colon-targeted AhR modulator, and its preclinical data demonstrating its mechanism of action [3] - A live Q&A session will follow the presentations, and a replay will be available on Equillium's website [4]